Our research by blood cancer type
At any one time we have over £90 million invested in research, and we’re currently funding over 1,000 researchers and clinicians across more than 220 active research projects, as well as numerous awards to train the research leaders of the future.
Our researchers are making discoveries that will have a positive impact for people with both Hodgkin and non-Hodgkin lymphoma.
Our researchers are making discoveries that will benefit patients with both chronic and acute forms of leukaemia.
In our Patient Need research we identified that myeloma should be a real priority for us when it comes to funding.
Other blood cancers
Conditions like MPN, MDS and MGUS are a priority for our researchers because in some cases if we can treat them, we can prevent other blood cancers developing. We'll have more information on our work around MGUS and MDS soon.